Osteoporosis Drugs Market cover

Osteoporosis Drugs Market by Products (Bisphosphonates, Parathyroid Hormone Therapy, Selective Estrogen Inhibitors Modulator, Generics, Branded, Calcitonin, and Rank Ligand Inhibitors) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2325
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 192
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global osteoporosis drugs market size is anticipated to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing cases of osteoporosis disease and rising demand for drugs for the treatment of the disease.

Osteoporosis Drugs Market summary

Osteoporosis is a type of disorder that causes a high chance of bones fracture in post menopause women, geriatric population, and others. In this condition, patients normally tend to break their bones, forearms, wrist, and spine of the body. It is a metabolic disease that causes a decrease in bone mineral density leading to fracture. As per the report published by International Osteoporosis Foundation, in 2020, there are 25% of women and 5% of men aged above 65 years are suffering from osteoporosis disorders. Furthermore, in October 2020, the Italian pharmaceutical regulatory body has granted permission for the raoxifene clinical trials on humans. Introduction of a generic osteoporosis medicine is expected to be helpful in COVID-19 treatment and make patients less contagious.

However, multiple therapy procedures are being tested all around the world in order to find a reliable COVID-19 treatment. Several studies have suggested that, in addition to antiviral therapies, other medications such as osteoporosis drugs is expected to be useful in the treatment of COVID-19.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing clinical trials and development of improved diagnostic facilities provided by private & public medical institutions are propelling the market growth.
  • Ongoing awareness campaigns related to the treatment of osteoporosis disorder is one of the factors fueling the growth of the market.
  • Rising technological advancement and introduction of new drugs by pharmaceutical industry with better efficacy to treat osteoporosis is another major factor triggering the market growth.
  • Expiring patents of robust drugs is expected to hamper the market growth in the coming years.
  • Adverse side effects of medications and stringent government regulations along with delaying in drug approvals are some of the key challenges that can hinder the market expansion.
  • Increasing incidences of osteoporosis condition triggers the manufactures across world to focus more on research & development programs for drugs treatment. Thus, it presents tremendous opportunity for the market growth in the near future.

Scope of the Report

The report on the global osteoporosis drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Osteoporosis Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Bisphosphonates, Parathyroid Hormone Therapy, Selective Estrogen Inhibitors Modulator, Generics, Branded, Calcitonin, and Rank Ligand Inhibitors)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Actavis PLC.; Pfizer Inc.; Amgen Inc.; Eli Lily and Co.; Radius Health Inc.; F. Hoffmann La Roche; Merck & Co.; Teva Pharmaceutical Industries Ltd.; Novartis International AG; and GlaxoSmithKline PLC.

Market Segment Insights

Rank ligand inhibitors segment is projected to expand at a considerable CAGR

On the basis of products, the global osteoporosis drugs market is segmented into bisphosphonates, parathyroid hormone therapy, selective estrogen inhibitors modulator, generics, branded, calcitonin, rank ligand inhibitors (RANKL). The RANKL segment is projected to expand at a considerable CAGR during the forecast period due to the high successful rate associated with this drug treatment. It is used for the treatment of osteoporosis patients with high risk of bone fracture. Other factors such as increasing bone mineral density, reducing cell bone turnover, and compatibility with other drugs to get a synergistic effect on the overall treatment are expected to propel the growth of the segment.

Osteoporosis Drugs Market product

According to a study conducted by the Hospital Del Mar, a general hospital in Spain in 2020, Denosumab targets the RANKL system, which is very important to maintain balance in the skeletal system. Furthermore, it impacts the immune system and is involved in lymph node formation and T-cell activation. The inhibition of this system lowers pro-inflammatory cytokines in the body and aids in inflammation control, which is one of the main causes of COVID-19. Thus, it is anticipated to increase the usage of this drug and up surge the segment growth during the forecast period.

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the factors such as increasing cases of osteoporosis patients, well- established healthcare facilities, presence of key players, and availability of branded drugs in the region. For example, according to the report published by the National Osteoporosis Foundation (NOF) in 2020, there were more than 10 million people suffering from osteoporosis in the US. Thus, it is expected to fuel the market growth in the region.

Osteoporosis Drugs Market region

However, the market of Asia Pacific is estimated to expand at a considerable CAGR in coming years. This growth of the region is attributed to the geographical expansion of market leaders, growing investment in R&D and efforts to sell branded drugs & generic treatments at an affordable cost in the region.

Segments

Segments Covered in the Report

The global osteoporosis drugs market has been segmented on the basis of

Products

  • Bisphosphonates
  • Parathyroid Hormone Therapy
  • Selective Estrogen Inhibitors Modulator
  • Generics
  • Branded
  • Calcitonin
  • Rank Ligand Inhibitors

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Actavis PLC.
  • Pfizer Inc.
  • Amgen Inc.
  • Eli Lily and Co.
  • Radius Health Inc.
  • F. Hoffmann La Roche
  • Merck & Co.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis International AG
  • GlaxoSmithKline PLC.

Competitive Landscape

Some of the key players dominating the osteoporosis drugs market are Actavis PLC.; Pfizer Inc.; Amgen Inc.; Eli Lily and Co.; Radius Health Inc.; F. Hoffmann La Roche; Merck & Co.; Teva Pharmaceutical Industries Ltd.; Novartis International AG; and GlaxoSmithKline PLC. Some of these main players have adopted several business strategies including partnerships, products launching, mergers, and capacity expansion to expand their market coverage globally.

For instance, Cadila Pharmaceuticals Ltd., an Ahmedabad-based company, launched an osteoporosis biosimilar of Forteo in August 2020, with an aim to treat patients with high risk of fracture and osteoporosis. Teriparatide Injection, also known as PF708 and bonsity, was launched by Alvogen in the United States in June 2020. It was a prescription drug licensed for a variety of applications such as prevention of bone fractures in postmenopausal women with the disease.

Osteoporosis Drugs Market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Osteoporosis Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Osteoporosis Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Osteoporosis Drugs Market - Supply Chain
  4.5. Global Osteoporosis Drugs Market Forecast
     4.5.1. Osteoporosis Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Osteoporosis Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Osteoporosis Drugs Market Absolute $ Opportunity
5. Global Osteoporosis Drugs Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Osteoporosis Drugs Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Osteoporosis Drugs Demand Share Forecast, 2019-2026
6. North America Osteoporosis Drugs Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Osteoporosis Drugs Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Osteoporosis Drugs Demand Share Forecast, 2019-2026
7. Latin America Osteoporosis Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Osteoporosis Drugs Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Osteoporosis Drugs Demand Share Forecast, 2019-2026
8. Europe Osteoporosis Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Osteoporosis Drugs Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Osteoporosis Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Osteoporosis Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Osteoporosis Drugs Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Osteoporosis Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Osteoporosis Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Osteoporosis Drugs Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Osteoporosis Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Osteoporosis Drugs Market: Market Share Analysis
  11.2. Osteoporosis Drugs Distributors and Customers
  11.3. Osteoporosis Drugs Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Actavis PLC.
     11.4.2. Pfizer Inc.
     11.4.3. Amgen Inc.
     11.4.4. Eli Lily and Co.
     11.4.5. Radius Health Inc.
     11.4.6. F. Hoffmann La Roche
     11.4.7. Merck & Co.
     11.4.8. Teva Pharmaceutical Indus

Segments Covered in the Report

The global osteoporosis drugs market has been segmented on the basis of

Products

  • Bisphosphonates
  • Parathyroid Hormone Therapy
  • Selective Estrogen Inhibitors Modulator
  • Generics
  • Branded
  • Calcitonin
  • Rank Ligand Inhibitors

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Actavis PLC.
  • Pfizer Inc.
  • Amgen Inc.
  • Eli Lily and Co.
  • Radius Health Inc.
  • F. Hoffmann La Roche
  • Merck & Co.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis International AG
  • GlaxoSmithKline PLC.

Some of the key players dominating the osteoporosis drugs market are Actavis PLC.; Pfizer Inc.; Amgen Inc.; Eli Lily and Co.; Radius Health Inc.; F. Hoffmann La Roche; Merck & Co.; Teva Pharmaceutical Industries Ltd.; Novartis International AG; and GlaxoSmithKline PLC. Some of these main players have adopted several business strategies including partnerships, products launching, mergers, and capacity expansion to expand their market coverage globally.

For instance, Cadila Pharmaceuticals Ltd., an Ahmedabad-based company, launched an osteoporosis biosimilar of Forteo in August 2020, with an aim to treat patients with high risk of fracture and osteoporosis. Teriparatide Injection, also known as PF708 and bonsity, was launched by Alvogen in the United States in June 2020. It was a prescription drug licensed for a variety of applications such as prevention of bone fractures in postmenopausal women with the disease.

Osteoporosis Drugs Market keyplayers

Buy Report